dalteparin has been researched along with Respiratory Tract Infections in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days." | 3.88 | Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. ( Cohoon, KP; De Sanctis, Y; Haskell, L; McBane, RD; Spiro, TE, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohoon, KP | 1 |
| De Sanctis, Y | 1 |
| Haskell, L | 1 |
| McBane, RD | 1 |
| Spiro, TE | 1 |
1 other study available for dalteparin and Respiratory Tract Infections
| Article | Year |
|---|---|
Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Drug Administration Sched | 2018 |